Lysogene Appoints Dr. Kimberley S. Gannon As Chief Scientific Officer
Dr. Gannon brings her broad-based expertise in Neurosciences to further advance Lysogene’s gene therapies for neurodegenerative conditions
PARIS--(BUSINESS WIRE)--Lysogene, a biotechnology company specializing in gene therapy technology applied to central nervous system diseases, has appointed Kimberley S. Gannon, PhD, as its Chief Scientific Officer.
“We are eager to welcome Dr. Gannon aboard during this exciting period of growth for Lysogene”
Dr. Gannon brings over 15 years of industry experience in CNS research and development at major pharmaceutical firms and early stage biotech companies to strengthen and accelerate Lysogene’s development programs in Mucopolysaccharidosis Type A (also known as Sanfilippo A) and GM1 Gangliosidosis. Dr. Gannon will be based in Lysogene’s U.S. office in Cambridge, Mass., and report directly to CEO Karen Aiach.
“We are eager to welcome Dr. Gannon aboard during this exciting period of growth for Lysogene,” said CEO Karen Aiach. “Dr. Gannon’s scientific background and experience are impressive, and her contribution will be invaluable as we advance our lead gene therapy programs, and explore new ones for those rare conditions where there is a treatment void.”
Prior to joining Lysogene, Dr. Gannon was Senior Vice President of Preclinical Research and Development at NeuroPhage Pharmaceuticals, Inc., where she directed preclinical research and drug development activities. She has also held various leadership positions at several early stage ventures, including CereMedix where she was Vice President of Research & Development, EPIX (Predix) Pharmaceuticals where she served as Senior Director of Biology, and Eolas Biosciences where she was Head of US Operations. In addition, Dr. Gannon headed up a research laboratory in Neuroscience Drug Discovery at Eli Lilly. Dr. Gannon’s expertise spans preclinical pharmacology, translational medicine, and nonclinical drug development.
Dr. Gannon received her PhD in Neurosciences from Florida State University and conducted her postdoctoral training at the Roche Institute of Molecular Biology, Hoffmann-LaRoche Inc., in New Jersey and at Mount Sinai School of Medicine in the Department of Physiology and Biophysics in New York City. Her primary area of focus is drug development targeting neurodegenerative diseases.
“I am excited to join Karen and the Lysogene team on this mission. I’m looking forward to applying my expertise as Lysogene moves into the next stages of development,” stated Dr. Gannon.
About Mucopolysaccharidosis Type A (also known as Sanfilippo A) and GM1 Gangliosidosis:
MPS IIIA is a lysosomal disease caused by an autosomal recessive defect of the SGSH gene and affecting approximately 1:100,000 live births. MPS IIIA presents in early childhood, causing progressive neurodegeneration associated with intractable behavioral problems and developmental regression. Life span is shortened, and there is currently no treatment.
GM1-gangliosidosis is a rare inherited neurodegenerative disorder characterized by severe cognitive and motor developmental delays resulting in early death. It is caused by mutations in the GLB1 gene, which encodes an enzyme called beta-galactosidase necessary for recycling the GM1-ganglioside molecule in neurons. This brain lipid is essential for normal function, but its accumulation causes neurodegeneration, resulting in severe neurological symptoms. There is currently no treatment.
About Lysogene:
Lysogene is a clinical-stage biotechnology company pioneering in the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a unique platform and network, with lead products in Mucopolysaccharidosis Type A (Sanfilippo A) and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases.
For more information www.lysogene.com.
Contacts
RooneyPartners
Marion Janic, +1 212-223-4017
mjanic@rooneyco.com
PARIS--(BUSINESS WIRE)--Lysogene, a biotechnology company specializing in gene therapy technology applied to central nervous system diseases, has appointed Kimberley S. Gannon, PhD, as its Chief Scientific Officer.
“We are eager to welcome Dr. Gannon aboard during this exciting period of growth for Lysogene”
Dr. Gannon brings over 15 years of industry experience in CNS research and development at major pharmaceutical firms and early stage biotech companies to strengthen and accelerate Lysogene’s development programs in Mucopolysaccharidosis Type A (also known as Sanfilippo A) and GM1 Gangliosidosis. Dr. Gannon will be based in Lysogene’s U.S. office in Cambridge, Mass., and report directly to CEO Karen Aiach.
“We are eager to welcome Dr. Gannon aboard during this exciting period of growth for Lysogene,” said CEO Karen Aiach. “Dr. Gannon’s scientific background and experience are impressive, and her contribution will be invaluable as we advance our lead gene therapy programs, and explore new ones for those rare conditions where there is a treatment void.”
Prior to joining Lysogene, Dr. Gannon was Senior Vice President of Preclinical Research and Development at NeuroPhage Pharmaceuticals, Inc., where she directed preclinical research and drug development activities. She has also held various leadership positions at several early stage ventures, including CereMedix where she was Vice President of Research & Development, EPIX (Predix) Pharmaceuticals where she served as Senior Director of Biology, and Eolas Biosciences where she was Head of US Operations. In addition, Dr. Gannon headed up a research laboratory in Neuroscience Drug Discovery at Eli Lilly. Dr. Gannon’s expertise spans preclinical pharmacology, translational medicine, and nonclinical drug development.
Dr. Gannon received her PhD in Neurosciences from Florida State University and conducted her postdoctoral training at the Roche Institute of Molecular Biology, Hoffmann-LaRoche Inc., in New Jersey and at Mount Sinai School of Medicine in the Department of Physiology and Biophysics in New York City. Her primary area of focus is drug development targeting neurodegenerative diseases.
“I am excited to join Karen and the Lysogene team on this mission. I’m looking forward to applying my expertise as Lysogene moves into the next stages of development,” stated Dr. Gannon.
About Mucopolysaccharidosis Type A (also known as Sanfilippo A) and GM1 Gangliosidosis:
MPS IIIA is a lysosomal disease caused by an autosomal recessive defect of the SGSH gene and affecting approximately 1:100,000 live births. MPS IIIA presents in early childhood, causing progressive neurodegeneration associated with intractable behavioral problems and developmental regression. Life span is shortened, and there is currently no treatment.
GM1-gangliosidosis is a rare inherited neurodegenerative disorder characterized by severe cognitive and motor developmental delays resulting in early death. It is caused by mutations in the GLB1 gene, which encodes an enzyme called beta-galactosidase necessary for recycling the GM1-ganglioside molecule in neurons. This brain lipid is essential for normal function, but its accumulation causes neurodegeneration, resulting in severe neurological symptoms. There is currently no treatment.
About Lysogene:
Lysogene is a clinical-stage biotechnology company pioneering in the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a unique platform and network, with lead products in Mucopolysaccharidosis Type A (Sanfilippo A) and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases.
For more information www.lysogene.com.
Contacts
RooneyPartners
Marion Janic, +1 212-223-4017
mjanic@rooneyco.com